[미래에셋 김승민] ADA 2026 Regular abstract Title

미국 당뇨학회 ADA 2026(6/5-8) 레귤러 초록 타이틀도 오늘새벽 공개되었네요. LBA 타이틀은 4월 중순 공개 대부분 초록 내용 공개는 5/29, 구두발표 초록 내용은 발표 전까지 엠바고 일단 확인되는건 한미약품 UCN2, 일동제약 저분자 GLP-1 한미약품 6/7 12:10pm (CDT) e포스터: Body Composition and Functional Outcomes of HM17321, a CRFR2-Selective UCN2 Analog, Alone and in Combination with Myostatin/Activin Inhibition in DIO Mice 6/7 12:30pm (CDT) 포스터: HM17321, a CRFR2 Selective UCN2 Analog, Prevents Muscle Loss and Functional Decline in Sarcopenic Mice 포스터: Protective Effects of HM17321, a Novel UCN2 Analog, on Obesity-Associated Musculoskeletal Diseases in Mouse Models 6/8 12:30pm (CDT) 포스터: Body Composition and Functional Outcomes of HM17321, a CRFR2-Selective UCN2 Analog, Alone and in Combination with Myostatin/Activin Inhibition in DIO Mice 포스터: Cardiorenal Protective Effects of a CRFR2-Selective UCN2 Analog, HM17321, in Spontaneously Hypertensive Rats (SHR) 포스터: Temporal Mechanistic Shifts Underlying Sustained Muscle Growth by HM17321 Revealed by Tissue Proteome Analysis 일동제약/유노비아 6/7 12:30pm (CDT) 포스터: ID110521156, a Novel Oral Small-Molecule GLP-1RA: Evidence of Favorable Safety Profile and Dose-Dependent Reduction in Body Weight and Glycemic Control after 28 Days of Treatment 그리고 요즘핫한 심혈관 siRNA 타깃 관련 타이틀은 * INHBE WAVE Life Sciences: Interim Results from INLIGHT, a Phase 1 Study of Investigational WVE-007, an INHBE Galnac siRNA for the Treatment of Overweight and Obesity Regeneron: Double Knockout of INHBC and INHBE Protect against Diet-Induced Obesity and Insulin Resistance in Mice BaseCure Therapeutics: 1106-OR - Prevention of Weight Rebound and Restoration of Muscle Mass after Semaglutide Withdrawal Using Bc-006, an INHBE siRNA, in a Nonhuman Primate Obesity Model [Board No. 1106] BaseCure Therapeutics: Safety, Tolerability, PK, PD, and Exploratory Efficacy of BC-006, an INHBE siRNA: FIH Randomized, Double-Blind, Placebo-Controlled, Single Dose-Escalation Study Innovent Biologics: IBI3046, an INHBE siRNA, Enables High Quality and Long-Lasting Weight Control in Preclinical Study WuxiAppTec: INHBE-siRNA as a Promising Antiobesity Therapy: Preclinical Evaluation in Diet-Induced-Obesity Humanized INHBE Mice Huadong Medicine: Preclinical Efficacy and Safety of HDM1014, a Novel GalNAc-siRNA Targeting INHBE, for Weight Management with Muscle Preservation * AKL7 Suzhou Siran Biotechnology: 1102-OR - Adipose-Targeted ALK7 siRNA Synergizes with Tirzepatide to Reduce Fat Mass while Preserving Lean Mass in Diet-Induced Obese Mice [Board No. 1102] Biocytogen: Generation of Humanized ALK7 Mice for Obesity Preclinical Research and Small Nucleic Acid Drug Evaluation ** 제보환영